Shire to eke out ‘precious’ Vyvanse as European ADHD launch nears
This article was originally published in Scrip
Shire is not expecting "huge sales" of Vyvanse (lisdexamfetamine dimesylate) in Europe this year, following its approval under the decentralized procedure at the end of December (scripintelligence.com, 20 December 2012), says CEO Angus Russell (aka Bilbo Baggins, since he is due to leave Shire soon; scripintelligence.com 25 October 2013). The new ADHD drug will be launched in the UK first, probably in April, and then Germany, he added, speaking at the JP Morgan global healthcare conference on 8 January.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.